413 related articles for article (PubMed ID: 34586737)
21. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy.
Rouzbahani E; Majidpoor J; Najafi S; Mortezaee K
Biomed Pharmacother; 2022 Dec; 156():113906. PubMed ID: 36306594
[TBL] [Abstract][Full Text] [Related]
22. Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma.
Ye W; Huang T
PLoS One; 2022; 17(2):e0264384. PubMed ID: 35196365
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X; Guo Y; Hu Y; Bao X; Zhu X; Fu Q; Zhang H; Tong Z; Liu L; Zheng Y; Zhao P; Fang W
Theranostics; 2021; 11(7):3489-3501. PubMed ID: 33537099
[TBL] [Abstract][Full Text] [Related]
24. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy.
Zhou X; Li C; Chen T; Li W; Wang X; Yang Q
Mol Cancer; 2023 Feb; 22(1):36. PubMed ID: 36810108
[TBL] [Abstract][Full Text] [Related]
25. m
Zhang B; Wu Q; Li B; Wang D; Wang L; Zhou YL
Mol Cancer; 2020 Mar; 19(1):53. PubMed ID: 32164750
[TBL] [Abstract][Full Text] [Related]
26. Immune checkpoints in tumor microenvironment and their relevance to the development of cancer stem cells.
Khosravi N; Mokhtarzadeh A; Baghbanzadeh A; Hajiasgharzadeh K; Shahgoli VK; Hemmat N; Safarzadeh E; Baradaran B
Life Sci; 2020 Sep; 256():118005. PubMed ID: 32593711
[TBL] [Abstract][Full Text] [Related]
27. Characterization of m
Zhu M; Cui Y; Mo Q; Zhang J; Zhao T; Xu Y; Wu Z; Sun D; Zhang X; Li Y; You Q
Front Immunol; 2021; 12():782551. PubMed ID: 34975871
[TBL] [Abstract][Full Text] [Related]
28. YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.
Hays E; Bonavida B
Drug Resist Updat; 2019 Mar; 43():10-28. PubMed ID: 31005030
[TBL] [Abstract][Full Text] [Related]
29. Tumour microenvironment and metabolic plasticity in cancer and cancer stem cells: Perspectives on metabolic and immune regulatory signatures in chemoresistant ovarian cancer stem cells.
Ahmed N; Escalona R; Leung D; Chan E; Kannourakis G
Semin Cancer Biol; 2018 Dec; 53():265-281. PubMed ID: 30317036
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive of N1-Methyladenosine Modifications Patterns and Immunological Characteristics in Ovarian Cancer.
Liu J; Chen C; Wang Y; Qian C; Wei J; Xing Y; Bai J
Front Immunol; 2021; 12():746647. PubMed ID: 34777359
[TBL] [Abstract][Full Text] [Related]
31. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
Pan J; Huang T; Deng Z; Zou C
Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
[TBL] [Abstract][Full Text] [Related]
32. m6A Regulator-Mediated Methylation Modification Patterns and Tumor Microenvironment Infiltration Characterization in Acute Myeloid Leukemia.
Du A; Wu X; Gao Y; Jiang B; Wang J; Zhang P; Zhao Q
Front Immunol; 2021; 12():789914. PubMed ID: 34887874
[TBL] [Abstract][Full Text] [Related]
33. The evolving landscape of N
Gu Y; Wu X; Zhang J; Fang Y; Pan Y; Shu Y; Ma P
Mol Ther; 2021 May; 29(5):1703-1715. PubMed ID: 33839323
[TBL] [Abstract][Full Text] [Related]
34. Mutual regulation between N6-methyladenosine (m6A) modification and circular RNAs in cancer: impacts on therapeutic resistance.
Lin H; Wang Y; Wang P; Long F; Wang T
Mol Cancer; 2022 Jul; 21(1):148. PubMed ID: 35843942
[TBL] [Abstract][Full Text] [Related]
35. Immunologic Targeting of Cancer Stem Cells.
Zhang J; Li Q; Chang AE
Surg Oncol Clin N Am; 2019 Jul; 28(3):431-445. PubMed ID: 31079798
[TBL] [Abstract][Full Text] [Related]
36. Comprehensive Analysis of PD-L1 Expression, Immune Infiltrates, and m6A RNA Methylation Regulators in Esophageal Squamous Cell Carcinoma.
Guo W; Tan F; Huai Q; Wang Z; Shao F; Zhang G; Yang Z; Li R; Xue Q; Gao S; He J
Front Immunol; 2021; 12():669750. PubMed ID: 34054840
[TBL] [Abstract][Full Text] [Related]
37. Recent Advances of RNA m
Ma S; Barr T; Yu J
Cancer Treat Res; 2023; 190():49-94. PubMed ID: 38112999
[TBL] [Abstract][Full Text] [Related]
38. Characterization of the m6A-Associated Tumor Immune Microenvironment in Prostate Cancer to Aid Immunotherapy.
Liu Z; Zhong J; Zeng J; Duan X; Lu J; Sun X; Liu Q; Liang Y; Lin Z; Zhong W; Wu W; Cai C; Zeng G
Front Immunol; 2021; 12():735170. PubMed ID: 34531875
[TBL] [Abstract][Full Text] [Related]
39. N6-Methyladenosine-Related lncRNAs as potential biomarkers for predicting prognoses and immune responses in patients with cervical cancer.
Zhang H; Kong W; Zhao X; Han C; Liu T; Li J; Song D
BMC Genom Data; 2022 Jan; 23(1):8. PubMed ID: 35042477
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic N6-methyladenosine modification of RNA and DNA regulates cancer.
Liang Z; Kidwell RL; Deng H; Xie Q
Cancer Biol Med; 2020 Feb; 17(1):9-19. PubMed ID: 32296573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
